1.
S1 Fig -
2.
3.
4.
5.
6.
7.
S2 Fig -
S3 Fig -
S4 Fig -
S5 Fig -
S6 Fig -
CBP per cumulative year for daratumumab and pembrolizumab per vial.
CBP per cumulative indication for daratumumab and pembrolizumab per vial.
Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.
Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.